The potential efficacy of R8-modified paclitaxel-loaded liposomes on pulmonary arterial hypertension

Pharmaceutical Research

Volumn 30, Issue 8, 2013, Pages 2050-2062

  Yin, Yujia ^a,b   Wu, Xindan ^d   Yang, Zhangya ^d   Zhao, Jian ^d   Wang, Xiaoshuang ^a   Zhang, Qianyu ^b   Yuan, Mingqing ^b   Xie, Liang ^a   Liu, Hanmin ^a   He, Qin ^b,c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d SOUTHWEST MEDICAL UNIVERSITY   (China)

Author keywords

octaarginine; paclitaxel; pulmonary arterial hypertension; vascular smooth muscle cells

Indexed keywords

DRUG CARRIER; LIPOSOME; OCTAARGININE; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VESSEL DIAMETER; CAMERA; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSKELETON; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; DRUG UPTAKE; HEART RIGHT VENTRICLE HYPERTROPHY; LIPOSOMAL DELIVERY; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; HYPERTENSION, PULMONARY; LIPOSOMES; LUNG; MALE; MUSCLE, SMOOTH, VASCULAR; OLIGOPEPTIDES; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; TUBULIN MODULATORS;

EID: 84879793028     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1058-8     Document Type: Article

References (39)

1. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. Circulation. 2009;119(16):2250-94.
2. Jeffery TK, Morrell NW. Molecular and cellular basis of vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis. 2002;45(3):173-202.
3. Mcgoon MD, Kane GC. Pulmonary hypertension: diagnosis and management. Mayo Clin Proc. 2009;84(2):191-207.
4. Kang BK, Chon SK, Kim SH, Jeong SY, Kim MS, Cho SH, et al. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm. 2004;286:147-56.
5. Sollott SJ, Cheng L, Pauly RR, Jenkins GM, Monticone RE, Kuzuya M, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest. 1995;95:1869-76.
6. Axel DI, Kunert W, Göggelmann C, Oberhoff M, Herdeg C, Küttner A, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation. 1997;96:636-45.
7. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature. 1979;277:665-7.
8. WeiSS RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263-8.
9. Swaminathan J, Ehrhardt C. Controlled pulmonary drug delivery. New York: Springer; 2011.
10. Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem. 2001;276:5836-40.
11. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem. 2002;277:2437-43.
12. Futaki S, Ohashi W, Suzuki T, Niwa M, Tanaka S, Ueda K, et al. Stearylated arginine-rich peptides: a new class of transfection systems. Bioconjug Chem. 2001;12:1005-11.
13. Cryan SA, Devocelle M, Moran PJ, Hickey AJ, Kelly JG. Increased intracellular targeting to airway cells using octaarginine-coated liposomes: in vitro assessment of their suitability for inhalation. Mol Pharm. 2006;3(2):104-12.
14. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA. Enhanced heparan sulfate proteoglycan-mediated uptake of cellpenetrating peptide-modified liposomes. Cell Mol Life Sci. 2004;61:1785-94.
15. Qin Y, Chen HL, Zhang QY, Wang XX, Yuan WW, Kuai R, et al. Liposome formulated with TAT-modified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm. 2011;420:304-12.
16. Kim DW, Kwon JS, Kim YG, Kim MS, Lee GS, Youn TJ, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation. 2004;109:1558-63.
17. Yang XP, Thomas DP, Zhang XC, Culver BW, Alexander BM, Murdoch WJ, et al. Curcumin inhibits platelet-derived growth factor stimulated vascular smooth muscle cell function and injury-induced neointima formation. Arterioscler Thromb Vasc Biol. 2006;26:85-90.
18. Morille M, Montier T, Legras P, Carmoy N, Brodin P, Pitard B, et al. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Biomaterials. 2010;31(2):321-9.
19. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD, et al. Pulmonary hemodynamics modify the rat pulmonary artery response to injury: a neointimal model of pulmonary hypertension. Am J Pathol. 1997;151(4):1019-25.
20. Mei YF, Jin H, Tian W, Wang H, Wang H, Zhao YP, et al. Urantide alleviates monocrotaline induced pulmonary arterial hypertension in Wistar rats. Pulm Pharmacol Ther. 2011;24:386-93.
21. Mathew R, Gloster ES, Sundararajan T, Thompson CI, Zeballos GA, Gewitz MH. Role of inhibition of nitric oxide production in monocrotaline-induced pulmonary hypertension. J Appl Physiol. 1997;82:1493-8.
22. Cowan KN, Heilbut A, Humpl T, Lam C, Ito S, Rabinovitch M. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med. 2000;6:698-702.
23. Kavanagh CA, Rochev YA, Gallagher WM, Dawson KA, Keenan AK. Local drug delivery in restenosis injury: thermoresponsive co-polymers as potential drug delivery systems. Pharmacol Therapeut. 2004;102:1-15.
24. Kim TJ, Lim Y, Kim DW, Kwon JS, Son JH, Jin YR, et al. Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. Vasc Pharmacol. 2007;47:229-37.
25. Kenichi S, Takahisa M, Hiroko CH, Hori M, Ozaki H. Fluvastatin prevents vascular hyperplasia by inhibiting phenotype modulation and proliferation through extracellular signal regulated kinase 1 and 2 and p38 mitogenactivated protein kinase inactivation in organ-cultured artery. Arterioscler Thromb Vasc Biol. 2005;5(2):327-33.
26. Rensen SSM, Doevendans PAFM, Eys GJJM. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;:100-8. doi: 10.1007/BF03085963.
27. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7:626-34.
28. Ntziachristos V, Bremer C, Issleder R. Fluorescence imaging with nearinfrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol. 2003;13:195-208.
29. Wessely R, Schömig A, Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents. J Am Coll Cardiol. 2006;47(No. 4).
30. Lei F, Fan W, Li XK, Wang S, Hai L, Wu Y, et al. Design, synthesis and preliminary bioevaluation of glucose-cholesterol derivatives as ligands for brain targeting liposomes. Chin Chem Lett. 2011;22(7):831-4.
31. Nativ O, Aronson M, Medalia O, Moldavsky T, Sabo E, Ringe I, et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer. 1997;70:297-301.
32. Lao LL, Venkatraman SS. Adjustable paclitaxel release kinetics and its efficacy to inhibit smooth muscle cells proliferation. J Control Release. 2008;7(130):9-14.
33. Kastrati A, Dibra A, Eberle S, Mehilli J, Lezo JS, Goy JJ, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials. JAMA. 2005;294:819-25.
34. Windecker S, Remondino A, Eberli FR, Jüni P, Räber L, Wenaweser P, et al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med. 2005;353:653-62.
35. Uchida K, Sasahara M, Morigami N, Hazama F, Kinoshita M. Expression of platelet-derived growth factor B-chain in neointimal smooth muscle cells of balloon injured rabbit femoral arteries. Atherosclerosis. 1996;124:9-23.
36. Li J, Huang SL, Gui GZ. Platelet-derived growth factor stimulated vascular smooth muscle cell proliferation and its molecular mechanism. Acta Pharmacol sin. 2000;21(4):340-4.
37. Ferns GAA, Rains EW, Sprugel KH, Motani AS, Reidy MA, Ross R. Inhibition of neintimal smooth muscle accumulation after angioplasty by an antibody to PDGF. Science. 1991;253:1129-32.
38. Rensen SSM, Doevendans PAFM, Eys GJJM. Regulation and characteristics of vascular smooth muscle cell phenotypic diversity. Neth Heart J. 2007;15(Number 3).
39. Lamberts RR, Vaessen RJ, Westerhof N, Stienen GJM. Right ventricular hypertrophy causes impairment of left ventricular diastolic function in the rat. Bas Res Cardiol. 2007;102(1):19-27.